Androgen receptor upregulation mediates radioresistance after ionizing radiation

Cancer Research

Volumn 75, Issue 22, 2015, Pages 4688-4696

  Spratt, Daniel E ^a   Evans, Michael J ^a   Davis, Brian J ^b   Doran, Michael G ^a   Lee, Man Xia ^a   Shah, Neel ^a   Wongvipat, John ^a   Carnazza, Kathryn E ^a   Klee, George G ^b   Polkinghorn, William ^a   Tindall, Donald J ^b   Lewis, Jason S ^a   Sawyers, Charles L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; HEXOKINASE; HEXOKINASE 2; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; AR PROTEIN, HUMAN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BIOCHEMICAL RECURRENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE ESCALATION; RADIOSENSITIVITY; RECEPTOR UPREGULATION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; BIOSYNTHESIS; COMET ASSAY; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; LUMINESCENCE; METABOLISM; PHYSIOLOGY; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; COMET ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945895120     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0892     Document Type: Article

References (22)

1. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497-504.
2. Bolla M, De Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516-27.
3. Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: Radiation Therapy Oncology Group randomized clinical trial 9910. J Clin Oncol 2014;58:0662.
4. Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 2006;60:201-15.
5. Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 2013;3:1245-53.
6. Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov 2013;3:1254-71.
7. Bartek J, Mistrik M, Bartkova J. Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer. Cancer Discov 2013;3:1222-24.
8. Lawton CA, DeSilvio M, Roach M III, Uhl V, Kirsch R, Seider M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. IJROBP 2007;69:646-55.
9. Vijayakumar S, Quadri SF, Karrison T, Trinidad C, Chan S, Halpern H, et al. Localized prostate cancer: use of serial prostate-specific antigen measurements during radiation therapy. Radiology 1992;184:271-74.
10. Davis B, Klee G, Lieber M, Hillman D, Goodmanson M, Burch P, et al. Serum human glandular kallikrein 2 (HK2) concentration at presentation and early subsequent follow-up for patients undergoing primary radiotherapy or brachytherapy with or without androgen deprivation therapy for localized prostate cancer therapy. IJROBP 2004;60:S454.
11. Klee GG, Goodmanson MK, Jacobsen SJ, Young CY, Finlay JA, Rittenhouse HG, et al. Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. Clin Chem 1999;45:800-6.
12. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107-18.
13. Roach M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585-91.
14. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff R-O, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066-73.
15. Shelley M, Kumar S, Wilt T, Staffurth J, Coles B, Mason M. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009;35:9-17.
16. Halperin EC, Brady LW, Wazer DE, Perez CA. Perez & Brady's principles and practice of radiation oncology. Philadelphia: Lippincott Williams & Wilkins; 2013.
17. Milosevic M, Chung P, Parker C, Bristow R, Toi A, Panzarella T, et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 2007;67:6022-25.
18. Milosevic M, Warde P, Ménard C, Chung P, Toi A, Ishkanian A, et al. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 2012;18:2108-14.
19. Veuger SJ, Hunter JE, Durkacz BW. Ionizing radiation-induced NF-κB activation requires PARP-1 function to confer radioresistance. Oncogene 2008;28:832-42.
20. Mills IG. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer 2014;14:187-98.
21. Mayeur GL, Kung W-J, Martinez A, Izumiya C, Chen DJ, Kung H-J. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells. J Biol Chem 2005;280:10827-33.
22. Spagnolo L, Rivera-Calzada A, Pearl LH, Llorca O. Three-dimensional structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair. Mol Cell 2006;22:511-19.